SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is actively trending as the community leans into its legacy as a 15-year-old parody of Bitcoin, with investors debating its long-term potential compared to serious financial assets. Discussion is largely fueled by the project's historical roots and a growing community narrative that frames the meme as an inevitable fixture in the crypto space.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is drawing intense scrutiny as investors weigh its mixed earnings and cautious outlook against a backdrop of fierce EV competition and a recent recall involving battery safety. The community remains deeply polarized, with some traders betting on a turnaround fueled by the launch of the i6 and i8 models, while others are aggressively shorting the stock, pointing to slowing sales momentum and aggressive rivalry from competitors like Nio.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is currently the subject of intense buyout speculation, fueled by the recent FDA grant of a landmark formal evidentiary hearing for its jet lag treatment and the approval of its bipolar medication, Bysanti. While investors are actively debating the impact of management's confrontational FDA strategy and price suppression, the community is closely monitoring the stock for potential acquisition by major pharmaceutical players looking to secure its high-value pipeline.

Maulcoin

Maulcoin is trending as investors rally behind a community-driven, organic growth strategy, actively pushing for a breakout while anticipating airdrops and chart visibility. The community is heavily focused on holding through volatility and maintaining strong diamond hands to drive the token toward higher market capitalization milestones.

Equinor ASA engages in the exploration, production, transport, refining, and marketing of petroleum and petroleum-derived products. It operates through the following segments: Exploration and Production Norway, Exploration and Production International, Exploration and Production USA, Marketing, Midstream, and Processing, Renewables, and Other. The Exploration and Production Norway segment includes the commercial development of oil and gas portfolios on the Norwegian continental shelf. The Exploration and Production International segment covers offshore and onshore activities in the USA, Mexico, and other operations worldwide. The Exploration and Production USA segment covers both onshore and offshore exploration, development, and Production of oil and gas in the USA. The Marketing, Midstream, and Processing segment markets and trades of crude oil and condensate, natural gas, NGL and refined products. The Renewables segment focuses on offshore wind, and integrated solutions for onshore renewables. The Other segment includes projects, drilling and procurement, the business area technology, digital and innovation, and corporate staffs and support functions. The company was founded on September 18, 1972 and is headquartered in Stavanger, Norway.

Equinor ASA - ADR

Equinor ASA

Equinor ASA is currently trending as investors monitor the company's role as a primary European energy supplier, with ongoing discussions focused on the impact of its North Sea infrastructure projects and natural gas distribution strategies. Market sentiment is bolstered by institutional activity surrounding dividend distributions and the company's long-term capital allocation plans, even as traders weigh the broader global energy landscape and supply-side pressures.

Rambus, Inc. engages in the provision of cutting-edge semiconductor and Internet Protocol products, spanning memory and interfaces to security, smart sensors and lighting. Its products include Memory Interface Chips, Interface IP, and Security IP. The company was founded by P. Michael Farmwald and Mark A. Horowitz in March 1990 and is headquartered in Sunnyvale, CA.

Rambus Inc.

Rambus is attracting investor interest as a high-performance memory play, with the community highlighting its strategic role in DDR5 and CXL technologies amid ongoing data center demand. While participants debate the impact of recent supply chain issues and executive turnover, many remain bullish, viewing the company as an undervalued infrastructure provider that is well-positioned for future memory bandwidth shifts.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

The Vanguard Total Stock Market ETF is trending as investors debate the merit of broad market indexing versus tactical rotation strategies amid ongoing economic volatility and sector-specific concerns. Community discussions focus on the benefits of long-term capital accumulation through ETFs like VTI as a resilient hedge against market noise and speculative trading.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently at the center of a high-stakes debate between those reacting to political support and those skeptical of its valuation amid competition from Anthropic. The community is actively debating the significance of a high-profile endorsement of the stock's defense capabilities, while bears emphasize concerns over technical indicators and the potential impact of new AI model developments on the company's long-term competitive moat.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is currently capturing investor attention as traders debate whether its recent volatility and price compression create a prime entry point ahead of upcoming earnings. While some investors are concerned by consistent selling pressure and the stock's struggle to reclaim key resistance levels, others are highlighting the company's improved profitability, strong cash flow, and potential for an acquisition as catalysts that could drive a sharp recovery.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - VR PRF PERPETUAL USD 100 - Ser A

Strategy Inc Variable Rate Series A Perpetual Stretch Preferred

Strategy Inc.'s STRC is currently trending as investors flock to the variable rate preferred stock for its high, monthly-paid dividend yield. The community is heavily focused on the asset as a reliable vehicle to generate liquidity, which the firm then funnels into aggressive, record-breaking Bitcoin acquisitions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Scilex Holding Company (SCLX) on Thursday said that its majority-owned subsidiary, Semnur Pharmaceuticals, and Denali Capital Acquisition Corp (DECA) have entered into a purchase agreement with an investor for a $20 million private placement.The proceeds of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://scilexholding.gcs-web.com/node/10161/pdf">agreement</a> will be used to advance the second late-stage clinical trial for the development of SP-102, a viscous gel formulation of a widely used corticosteroid for epidural injections, for the treatment of lumbosacral radicular pain. Lumbosacral radicular pain, often referred to as sciatica, is a pain that radiates along the sciatic nerve, which extends from the lower back down the leg.On Stocktwits, retail sentiment around Scilex remained within the ‘neutral’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels. <a href="https://stocktwits.com/symbol/SCLX">SCLX stock</a> is trading 0.5% lower in the pre-market session at the time of writing.<figure class="image"><img style="aspect-ratio:567/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_7_24_17_AM_png_36aea133ff.webp" alt="SCLX's Sentiment Meter and Message Volume as of 7:24 a.m. ET on Aug. 21, 2025 | Source: Stocktwits" width="567" height="60"><figcaption>SCLX's Sentiment Meter and Message Volume as of 7:24 a.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>Semnur and special purpose acquisition company (SPAC) Denali entered into a <a target="_blank" rel="noopener noreferrer nofollow" href="https://scilexholding.gcs-web.com/node/9226/pdf">plan of merger</a> on Aug. 30, 2024, for a proposed business combination, among Semnur, the SPAC, and the SPAC's unit Denali Merger Sub Inc. This provided for a pre-transaction equity value of Semnur at $2.5 billion.&nbsp;Under the deal, the combined company will be renamed Semnur Pharmaceuticals, Inc., and its common stock is expected to be listed on Nasdaq under the ticker symbol “SMNR”. The combination is now expected to close in September 2025.An investor has agreed to purchase an aggregate of 1.25 million shares of common stock of the combined company following the consummation of the merger transaction, Scilex said. The purchase price for the placement is $16.00 per share, for an aggregate purchase price of $20 million.The closing of the financing is subject to customary conditions and is expected to occur immediately following the consummation of the business combination, Scilex said.The company also said that CEO Jaisim Shah resigned as Scilex CEO and will now serve as chief executive and President of Semnur. Henry Ji, who currently serves as Executive Chairman of Scilex, was appointed as Scilex’s new CEO and President and has assumed all of the duties formerly performed by Shah, the company said.SCLX stock is up by 18% this year and down by 60% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/two-players-quietly-took-over-bitcoin-mining-power-heres-why-it-matters/chsSu9WRdi5">Two Players Quietly Took Over Bitcoin’s Mining Power — Here’s Why It Matters</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside

The proceeds of the agreement will be used to advance the second late-stage clinical trial for the development of SP-102, a viscous gel formulation of a widely used corticosteroid for epidural injections, for the treatment of lumbosacral radicular pain.

Equity

Scilex Holding Co. (SCLX), a relatively under-the-radar player in the non-opioid pain management space, has unexpectedly captured the attention of retail investors. The company experienced a staggering 41.78% increase in retail followers on Stocktwits over the past month, despite a 21% decline in its share price.However, the initial bullish sentiment has waned, with Stocktwits sentiment flipping to bearish (36/100) and message volumes surging. This shift suggests growing investor skepticism amidst recent company developments.<figure class="image"><img style="aspect-ratio:1316/306;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SCLX_Sentiment_and_message_score_Aug_1_f79a43cdac.png" alt="SCLX Sentiment and message score Aug 1.png" width="1316" height="306"><figcaption>SCLX Sentiment and message score Aug 1</figcaption></figure>The surge in retail interest can be attributed to several factors. Primarily, the announcement of a potential $2 billion deal for its subsidiary, Semnur Pharmaceuticals, to go public through a SPAC merger with Denali Capital Acquisition Corp (DECA) has generated excitement. The proceeds from this deal are earmarked for the development of SP-102, a key drug candidate in late-stage trials.Additionally, Scilex had reported preliminary Q2 net sales above estimates, indicating revenue growth. However, a significant decline in cash and cash equivalents raised concerns.The company also entered into a collaboration agreement with ACEA for the potential expansion of its ZTlido treatment, used to help relieve nerve pain after shingles, in the Greater China region.While July saw continued sales growth for ZTlido, the pace of growth slowed compared to the previous month. This, coupled with the overall bearish sentiment and declining cash reserves, seems to have tempered initial enthusiasm.With Q2 earnings report scheduled for August 9th after market hours, investors will be closely watching for further clarity on the company's financial health and the progress of its key initiatives.Photo via Vecteezy

Small-Cap Scilex Drew Biggest Jump In Retail Following For July: What Drove It?

Retail investors flocked to Scilex, drawn by news about a lucrative SPAC deal for its unit, declining cash reserves and slowing sales growth.

Semnur Pharmaceuticals, Inc. engages in developing and commercializing innovative non-opioid pain management products for the treatment of acute and chronic pain. It offers the product, SP-102, a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe lumbosacral radicular pain. The company was founded in 2013 and is headquartered in Palo Alto, CA.

DECA
Denali Capital Acquisition Corp - Ordinary Shares - Class A

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DECA News

DECADenali Capital Acquisition Corp - Ordinary Shares - Class A